Q2 26 EPS
$1.31
BEAT +2.63%
Est. $1.28
Q2 26 Revenue
$12.59B
BEAT +0.62%
Est. $12.52B
vs S&P Since Q2 26
+11.6%
BEATING MARKET
ABT +11.2% vs S&P -0.3%
Market Reaction
Did ABT Beat Earnings? Q2 2026 Results
Abbott Laboratories delivered a clean beat to open its second quarter of 2026, posting adjusted diluted EPS of $1.31 against a consensus estimate of $1.28, a 2.63% beat that extended the company's streak of topping Wall Street's earnings expectations… Read more Abbott Laboratories delivered a clean beat to open its second quarter of 2026, posting adjusted diluted EPS of $1.31 against a consensus estimate of $1.28, a 2.63% beat that extended the company's streak of topping Wall Street's earnings expectations to five consecutive quarters. Revenue of $12.59 billion grew 13.0% year over year, edging past the $12.52 billion consensus by 0.62%, with the transformative acquisition of Exact Sciences, completed in March, providing the primary engine behind the reported top-line surge. On a comparable basis that folds Exact Sciences into the prior-year base, sales rose a more measured 4.8%, with Medical Devices leading the way at $5.85 billion, up 9.0% reported, fueled by strong Electrophysiology and Diabetes Care momentum. Competitive pressures in continuous glucose monitoring remained a watchpoint for investors, but Abbott's performance gave management confidence to raise full-year adjusted EPS guidance to $5.45 to $5.60 while reaffirming comparable sales growth of 6.5% to 7.5%, with third-quarter adjusted EPS guided at $1.38 to $1.46.
Key Takeaways
- • Medical Devices led by low-teens Electrophysiology growth and high-single-digit growth in Rhythm Management, Diabetes Care, and Heart Failure
- • Continuous glucose monitor sales grew 11.0% reported and 9.5% comparable
- • Diagnostics boosted by Exact Sciences acquisition adding Cancer Diagnostics sub-segment with $919 million in Q2 sales
- • Cologuard delivered mid-teens growth benefiting from growing base of new and repeat users
- • Established Pharmaceuticals Key Emerging Markets grew 10.7% comparable led by double-digit growth in Latin America and Asia Pacific
- • Core Laboratory Diagnostics driven by strong growth in U.S. and Latin America
- • Cancer Diagnostics U.S. sales of $890 million represented 96.8% of segment revenue, growing 13.3% comparable
- • Diagnostics U.S. sales surged 104.8% reported driven by Exact Sciences contribution
ABT Forward Guidance & Outlook
Abbott reaffirmed full-year 2026 comparable sales growth guidance of 6.5% to 7.5%. The company raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, up from the previous range of $5.38 to $5.58. For Q3 2026, Abbott projects adjusted diluted EPS of $1.38 to $1.46. Management expects momentum to continue and drive accelerating sales and earnings growth in the second half of the year.
ABT YoY Financials
Q2 2026 vs Q2 2025, source: SEC Filings
ABT Revenue by Segment
With YoY comparisons, source: SEC Filings
ABT Revenue by Geography
With YoY comparisons, source: SEC Filings
“Our second-quarter results reflect the momentum we are building. We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year.”
— Robert B. Ford, Q2 2026 Earnings Press Release
ABT Earnings Trends
ABT vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ABT EPS Trend
Earnings per share: estimate vs actual
ABT Revenue Trend
Quarterly revenue: estimate vs actual
ABT Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $1.28 | $1.31 | +2.63% | $12.59B | +0.62% |
| Q1 26 BEAT | $1.15 | $1.15 | +0.33% | $11.16B | +1.51% |
| Q4 25 BEAT FY | $1.49 | $1.50 | +0.34% | $11.46B | -2.91% |
| FY Full Year | $5.17 | $5.15 | -0.42% | $44.33B | -0.78% |
| Q3 25 BEAT | $1.30 | $1.30 | +0.05% | $11.37B | -0.21% |
| Q2 25 BEAT | $1.25 | $1.26 | +0.80% | $11.14B | +1.08% |
| Q1 25 BEAT | $1.07 | $1.09 | +1.75% | $10.36B | -0.57% |